A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2Abstract: … for cat allergy as not only an important new therapeutic for catallergy/asthma but also as the sign post for development of this approach for the treatment of severe IgE mediated food allergy. PUBLIC HEALTH RELEVANCE: Effective treatments to for severe inhalant allergy… more
Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy
Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 2Abstract: …e key food antigens will be relatively straightforward. PUBLIC HEALTH RELEVANCE: Therapeutic peanut allergen-Fc-gamma chimeric proteins to treat food allergy Effective treatments to for severe allergic food allergy represent a major unmet medical need. As opposed to … more
Rapid Detection of Mycotoxins
Company: Lynntech, Inc. Agency/Program/Year/Phase: USDA / SBIR / 2012 / 1Abstract: … are extremely hazardous to humans. Exposure to even nano gram quantities of trichothecene mycotoxins, such as T-2 toxin, can cause severe reactions. Central nervous systems injury, as well as gastrointestinal and hematological toxicity can occur from ingestion or … more
Low cost ammonia sensor for agricultural emissions
Company: MESA PHOTONICS, LLC Agency/Program/Year/Phase: USDA / SBIR / 2012 / 1Abstract: … is emitted from agriculture can create health problems for workers and, surprisingly, for people far from the agricultural operation. Once released into the air, the ammonia undergoes a series of chemical reactions that lead to small particles (known as PM2.5) that are inhaled… more
Improving Chemotherapy with a Novel Oxygen-Delivery Protein
Company: OMNIOX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: … to correlate with poorer patient outcomes inmultiple cancer types. Oxygenating hypoxic regions of tumors has the potential to, sensitizing tumors to antineoplastic therapies. Previous efforts to eliminate tumor hypoxia via hyperbaric oxygen, blood transfusions, or inhaled… more
Preventing asthma exacerbations by reducing viral respiratory infections
Company: PULMOTECT, INC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: … developing novel therapeutics that stimulate the innate immune system to protect against infectious diseases, even in cases of severely compromised immunity. Proof-of-concept data has shown that this technology effectively protects against a broad range of inhaled pathogens.… more
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
Company: SAVARA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, initially in cystic fibrosis (CF) patients and subsequently in other high… more
Targeting surface-bound IgE as a novel allergy therapeutic
Company: SIXAL CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: …c health issue and particularly so in developed countries such as the US. Novel effective treatment options for allergies remain a major unmet need; no effective therapy is available for severe food allergies such as peanut allergy and no new platforms for inhalant allergy have… more
Development of human thioredoxin as a mucolytic therapy for Cystic Fibrosis
Company: ORPRO THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1Abstract: … and infection. In the case of CF, an autosomal recessive disease affectingapproximately 30,000 patients in the US and 70,000 world-wide, current therapies designed to increase the fluidity of mucus and facilitate clearance involve the use of hypertonic saline inhalation to… more
Thermostable Measles-Rublella Vaccines for Respiratory Delivery
Company: Universal Stablization Technologies, Inc Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2Abstract: …, stable powders have been produced in high yield that can be stored at least 10 months at 37°C. The specific aims of this project are: 1) Develop a formulation for stable measles-rubella vaccine powder utilizing the PBV process 2) Micronize product to an inhalable particle… more
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: …eutic molecule is a genetically engineered human fusion protein consisting of a portion of the human gamma1 Fc linked to a portion of the human epsilon Fc chain [(hinge-h2-3(1)-linker- (ch2-3-4()] that is designated as GE2 . Effective treatments for severe inhalant… more
Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies
Company: RADIX THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / STTR / 2011 / 1Abstract: …nting or substantially reducing the allergic response to subsequent nasal exposure of mountain cedar pollen. Positive Phase I results will provide proof of concept that nasal instillation of optimized antibodies can provide an effective barrier between an inhaled allergen… more
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
Company: GLYCOMIRA, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: … diseases, and pregnancy complications. Periodontal disease is exacerbated in diabetics and smokers due to increased exposure to advanced glycation end-products (AGEs), which arise from spontaneous glycation of proteins.AGEs from high blood sugar or from inhalation of AGES… more
Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma
Company: MERCATOR MEDSYSTEMS, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2Abstract: …(b) statistically showing a non-toxic dose of a common chemotherapeutic, anti-proliferativedrug like paclitaxel can have broad-ranging clinical impact, (c) bronchial adventitial therapy may be more effective in the prevention and treatment of bronchial maladies than inhalation… more
Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device
Company: Physical Optics Corporation Agency/Program/Year/Phase: DOD / SBIR / 2011 / 2Abstract: To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to advance development of a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN).… more
Rapidly boosting innate immunity in the lungs to protect against pneumonia
Company: PULMOTECT, INC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: … an estimated 44,700 leukemia patients spend more than one-half billion dollars on a range of treatments in an effort to prevent pneumonia. Pulmotect's Solution: Pulmotect has identified and is developing a novel technology to address the risks of inhaled microbes.… more
A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use
Company: SAVARA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroids and bronchodilators, which enable adult populations to function well despite… more
Development of a Field-Deployable Device to Rapidly Measure Blood Cyanide Levels
Company: DIAGNOSTIC CONSULTING NETWORK, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1Abstract: … test. If successful, this test will provide the medical community and first responders with a fast, reliable and economic alternative to determine cyanide poisoning. PUBLIC HEALTH RELEVANCE: Cyanide poisoning hasbeen recognized as a threat from smoke inhalation and… more
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is to develop and commercialize a new approach for allergen specific immunotherapy as treatment for cat allergy. This proposal will provide a novel therapeutic for a very importan
t inhalant allergen… more
Pharmacological characterization of a novel ROCK inhibitor for COPD
Company: THERON PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: … is one of the leading causes of morbidity and mortality worldwide. The currently available treatments are largely palliative and have minimal impact on the inflammatory proce
ss in COPD that inexorably leads to a decline in lung function. Unlike asthma, for which inhaled… more
Endoscopic Tool for Small Animal Intubation
Company: BIOTEX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: … by applicant): The importance of in vivo small animal research to the scientific community cannot be overestimated. Along with the advantages of small animal manipulations come inherent difficulties, among them intubations which are o
ften necessary for inhalation… more
NanoDisk-Amphotericin B therapy for aspergillosis
Company: LYPRO BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2Abstract: …. In the proposed project we will test the hypothesis that ND-AMB is a fast acting, potent and safe therapy for treating and preventing disseminated aspergillosis in mice. Because patients with pulmonary aspergillosis are less capable of taking in inhaled therapies,… more
Development of a monoclonal immunoprotectant for ricin
Company: MAPP BIOPHARMACEUTICAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1Abstract: … bioterrorism agents as a national research priority. There is a particular need for antidotes against the toxin ricin (NIAID
, 2004); the Centers for Disease Control estimates that 500 micrograms of ricin is a lethal dose in humans exposed via injection or inhalation. Ricin,… more
Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device
Company: Physical Optics Corporation Agency/Program/Year/Phase: DOD / SBIR / 2010 / 1Abstract: To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to develop a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed… more
Novel Therapy for Pulmonary Anthrax
Company: PLANET BIOTECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2Abstract: DESCRIPTION (provided by applicant): Planet Biotechnology Inc. (PBI) is developing a therapeutic recombinant protein, PBI-220, that neutralizes anthrax toxin in vitro and protects against inhalational anthrax in vivo. PBI uses transgenic plants as an innovative,… more